Selpercatinib
Back to searchMolecule Structure
Scientific Name
Selpercatinib
Description of the Drug
Selpercatinib is a RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15685
http://www.drugbank.ca/drugs/DB15685
Brand Name(s)
Retevmo
Company Owner(s)
Loxo Oncology Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3430888 |
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3430904 |
Tyrosine-protein kinase receptor RET | SINGLE PROTEIN | INHIBITOR | CHEMBL2041 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL20071478 | |
Human Metabolome Database | HMDB0304865 | |
DrugBank | DB15685 | |
PubChem | 134436906 | |
BindingDB | 296429 | |
DrugCentral | 5393 | |
ChemicalBook | CB34805442 | |
Guide to Pharmacology | 10318 | |
rxnorm | SELPERCATINIB | RETEVMO |